Pfizer Articles
Milestone payments for Epizyme and Antares Pharma
3 October 2012
ESMO 2012 Congress highlights
1 October 2012
FDA sets March 2013 PDUFA date for re-submitted Eliquis
28 September 2012
Pfizer and Roche hope to score with ESMO presentations, notes GlobalData
25 September 2012
Mylan debuts first generic Diovan HCT and Antivert copy in USA
23 September 2012
Top drugmakers set up non-profit TransCelerate to speed pharma R&D
20 September 2012
Pfizer to face class action over alleged securities fraud by Wyeth
19 September 2012
Decline in cardiovascular drugs noted at ESC congress
17 September 2012
Rheumatoid arthritis drug market forecast to grow modestly to $15.2 billion in 2021
16 September 2012
Pfizer launches generics JV in China with Hisun
14 September 2012
Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan
10 September 2012
Public Citizen sues FDA for failing to ban dangerous dose of Aricept
7 September 2012
FDA nod for Pfizer's rare leukemia drug Bosulif
6 September 2012
European approval for Pfizer's kidney cancer drug Inlyta
5 September 2012
FDA warns against use of Pfizer's Revatio in children with PAH
2 September 2012
US surveyed PCPs and pain specialists experienced reimbursement restrictions for Janssen's Nucynta ER
28 August 2012
Claris to go it alone in USA
27 August 2012
News briefs: Drug majors eyeing Strides Arcolab unit; Astellas invests in oncology facility
20 August 2012
Pfizer says Torisel combo fails in Ph III for kidney cancer
13 August 2012
Pfizer in $60 million settlement over bribery charges
8 August 2012
Positive Ph IV data for Pfizer and UCB's Toviaz
6 August 2012
Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's
24 July 2012
US FDA approves generics for Actavis and Lupin
6 July 2012
Watson challenges Pfizer's Pristiq patent
26 June 2012
EMA backs approval of Revestive, Zinforo and Seebri Breezhaler, but not Elelyso; Hexaxim opinion
25 June 2012
Batch of mixed opinions from FDA advisory panels
21 June 2012
75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch
21 June 2012
Senior exec appointments at Pfizer
23 May 2012
FDA advisory backs Pfizer's tofacitinib for RA
10 May 2012
Germany's G-BA backs Eisai's Halaven; IQWiG finds some added benefit for Eliquis and rilpivirine
23 April 2012
Factors impacting global pharma market growth in 2011
22 April 2012
German IQWiG finds mixed added benefits for Eliquis
2 April 2012
Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity
21 March 2012
Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers
20 March 2012
Pfizer and Biocon cancel biosimilars deal
14 March 2012
B-MS ties knot with Duke University on R&D
29 February 2012
FDA expands on cholesterol-lowering drug risks
29 February 2012
Almirall looks to robust 2012 despite higher losses
28 February 2012
Mylan gets tentative FDA approval for generic Epzicom
23 February 2012
Pfizer and Hisun flesh-out plans for generics JV in China
19 February 2012
Actavis to debut generic Aricept in EU markets as patents expire
16 February 2012
FDA now accepts Pfizer’s tafamidis NDA
16 February 2012
Germany’s IQWiG finds no added benefit for Pfizer’s Xiapex
14 February 2012
AB Science leaps as GIST candidate masitinib beats Sutent
6 February 2012
Pfizer’s fourth-quarter net income slumps 50%
1 February 2012
FDA OKs Pfizer’s Inlyta and accepts NDA for bosutinib
30 January 2012
Actavis launches latanoprost generics in Europe
26 January 2012
Pfizer, Medivation finally pull plug on Dimebon
18 January 2012
Lipitor and strategic collapse at Pfizer, a consultants view
5 January 2012
Expanded use for Pfizer’s Prevnar 13
3 January 2012
Karo Bio skyrockets on deal with Pfizer
28 December 2011
Pfizer tops social media presence ranking
19 December 2011
Intellect Neurosciences appeals European patent decision
15 December 2011
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
